Business Wire

Plus Launches National Upfit Program Delivering Class 8 Semi-Autonomous Trucks Within a Day

9.5.2022 15:00:00 EEST | Business Wire | Press release

Share

Plus, a global provider of self-driving truck technology, announced today that it has selected Velociti, a global leader in fleet technology solutions, as the deployment and maintenance partner for the national Plus Build program.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510005059/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Plus Build (Graphic: Business Wire)

The Plus Build program takes less than a day to turn new and existing Class 8 freight trucks into semi-autonomous trucks by equipping them with state-of-the-art lidar, radar, and camera sensors and Plus’s proprietary autonomous driving software. The result is PlusDrive, the industry’s first commercially available autonomous trucking solution. PlusDrive improves safety, enhances driver comfort, and saves at least 10% in fuel costs. Installation is performed at locations most convenient to customers, in or near major transportation hubs across the U.S. Maintenance services are available nationwide by utilizing mobile resources to meet customers where they are.

Shawn Kerrigan, COO and Co-founder of Plus, said: “Plus Build helps companies unlock the benefits of autonomous driving technology today by quickly modernizing trucks to improve their safety and uptime. Velociti’s unmatched technology installation and service network will help us get PlusDrive into the hands of more truck drivers across the country to make their jobs safer, easier, and better.”

Through the Plus Build program and partnership with Velociti, Plus is now deploying PlusDrive nationwide. Some of the world’s largest fleets and truck manufacturers are already participating in Plus Build and are operating PlusDrive-enabled trucks on the road today. In addition to Velociti’s technology installation services, Plus is implementing Velociti’s VeloCare solution, a flagship proactive system-health monitoring program including remote and mobile services to maximize technology uptime.

“Partnering with Plus to provide our services as an important part of the PlusDrive solution leverages Velociti’s decades of experience deploying and maintaining innovative fleet technologies. We are excited to enter into this strategic partnership to help PlusDrive customers realize the benefits this transformational technology brings to their businesses and to the transportation industry,” said Ryan Powell, Senior Vice President at Velociti.

Supervised by a truck operator, PlusDrive can autonomously handle the following in normal traffic conditions on a highway:

  • Lane centering
  • Driver initiated lane change
  • Traffic jam assist
  • Predictive fuel optimization
  • Adaptive cruise control (down to zero)
  • Lane merging
  • Driver attentiveness detection
  • Operational Design Domain (ODD) checker
  • Self-calibration
  • Over-the-air updates

For more information on the Plus Build program or PlusDrive, please contact sales@plus.ai.

About Plus

Plus is a global leader in the autonomous trucking revolution, with award-winning high-performance full-stack driverless technology. Named by Fast Company as one of the World’s Most Innovative Companies of 2022, Plus is the only autonomous driving company with customers operating its product on the road today. Working with one of the largest companies in the U.S., vehicle manufacturers and others, Plus is making long-haul trucking safer, more fuel efficient, more sustainable, and more comfortable for the drivers. Plus has received a number of industry awards and distinctions for its transformative technology and business momentum from Fast Company, Insider, Consumer Electronics Show, AUVSI, and others.

For more information, please visit www.plus.ai or follow us on LinkedIn or YouTube.

About Velociti

Velociti, a global provider of enterprise technology solutions for more than 25 years, helps meet complex business needs by optimizing technology investments, lowering costs, and improving employee and customer experience. Its innovative design, rapid installation and deployment, and proactive support services for a broad range of transportation and networking technologies are provided by a highly experienced team of engineers, project managers, certified technicians and customer success representatives. Velociti serves enterprises in transportation and logistics, construction, retail, food service, manufacturing, distribution, government, and hospitality including many Fortune 500 companies.

For more information visit http://www.velociti.com or call toll free (855)-233-7210.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PLUS
Lauren Kwan
pr@plus.ai

VELOCITI
Megan Blevins
megan.blevins@velociti.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release

Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi

Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release

Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob

Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release

Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati

Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release

Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F

FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 22:11:00 EEST | Press release

Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to further extend its category leadership among legal-age consumers of nicotine products. Like the flagship FDA-authorized ZYN pouches, ZYNULTRA, with its higher moisture content, is fre

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye